Traws Pharma Plans Q3 Resubmission to MHRA for Influenza Study
TRAW sits 32% above its 52-week low of $0.64 on light trading volume (0.4× avg).
Summary
Traws Pharma announced plans to resubmit an updated data package to the MHRA in Q3 2026 for its tivoxavir marboxil influenza study, aiming to resolve the recent deferral and advance its lead clinical program.
Key Events · Product Development and Regulatory · TRAW
-
Regulatory Resubmission Planned
Traws Pharma will resubmit an updated toxicology data package to the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) in Q3 2026 for its tivoxavir marboxil Phase 2a human influenza Challenge study.
-
Addresses Prior Deferral
This action follows the June 12, 2026 announcement of the study's deferral and aims to enable the clinical trial to proceed, providing a path forward after receiving detailed feedback from the MHRA.
-
Critical Program Advancement
Progress on the lead candidate is important for the clinical-stage company, which previously reported a going concern warning and zero revenue for Q1 2026.
Analysis · TRAW · Life Sciences
This filing provides an update on Traws Pharma's lead candidate, tivoxavir marboxil, following the deferral of its Phase 2a influenza study announced on June 12. The company now intends to resubmit an updated data package to the UK's MHRA in Q3 2026, aiming to enable the study to proceed. This indicates progress in addressing regulatory feedback and offers a timeline for advancing a critical clinical program for a company facing a going concern warning.
At the time of this filing, TRAW was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $0.64 to $3.27. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.